The overall mission of the Virology/Immunology Core is to enhance HIV-related research and promote collaborations among HIV investigators, by providing improved access to virologic and immunologic assays, clinical specimens, and recombinant DMA constructs.
The specific aims of this Core are: 1. To provide a centralized repository for clinical specimens and HIV-related recombinant DMA constructs that can be used by clinical, behavioral, and laboratory investigators. 2. To centralize, and improve access to, state-of-the-art virologic assays for clinical, behavioral, and laboratory investigators. 3. To provide a centralized facility that produces recombinant proteins relevant to HIV research. 4. To provide expertise in the design and interpretation of flow cytometry assays, and to improve access to the shared instrumentation necessary to conduct these studies. 5. To provide improved access to existing URMC core facilities. This core will utilize and augment already existing infrastructures, such as those in the Cold Storage Facility (Aim 1), Infectious Diseases Unit laboratories (Aim 2), Human Immunology Center (Aim 4), and existing core facilities (Aim 5) at the URMC. In addition, we will centralize expression of certain recombinant proteins (Aim 3), in order to provide economy of scale to investigators that use them in HIVrelated research. The Virology/Immunology Core will implement the overall mission of the UR D-CFAR by supporting a broad base of investigators from the UR and its international collaborators in South Africa, and promoting interdisciplinary collaborations among them.
|Piekna-Przybylska, Dorota; Nagumotu, Kavyasri; Reid, Danielle M et al. (2018) HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate. J Neurovirol :|
|Braksmajer, Amy; Simmons, Janie; Aidala, Angela et al. (2018) Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color. Am J Mens Health 12:1855-1863|
|Loelius, Shannon G; Lannan, Katie L; Blumberg, Neil et al. (2018) The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 169:96-104|
|Loelius, Shannon G; Spinelli, Sherry L; Lannan, Katie L et al. (2018) In Vitro Methods to Characterize the Effects of Tobacco and Nontobacco Products on Human Platelet Function. Curr Protoc Toxicol 76:e46|
|Rice, John D; Strawderman, Robert L; Johnson, Brent A (2018) Regularity of a renewal process estimated from binary data. Biometrics 74:566-574|
|Nogales, Aitor; Piepenbrink, Michael S; Wang, Jiong et al. (2018) A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci Rep 8:4374|
|Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65|
|Horita, Yasuhiro; Alsultan, Abdullah; Kwara, Awewura et al. (2018) Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations. Antimicrob Agents Chemother 62:|
|Yang, Hongmei; Holden-Wiltse, Jeanne; Topham, David J et al. (2018) Maximum Likelihood Estimation of Titer via a Power Family of Four-Parameter Logistic Model. J Biopharm Stat 28:492-500|
|Belashov, Ivan A; Crawford, David W; Cavender, Chapin E et al. (2018) Structure of HIV TAR in complex with a Lab-Evolved RRM provides insight into duplex RNA recognition and synthesis of a constrained peptide that impairs transcription. Nucleic Acids Res 46:6401-6415|
Showing the most recent 10 out of 192 publications